The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

The protest happened roughly 27 minutes into the meeting, held at NIH headquarters in Bethesda, Md. In a video obtained by CNN, Bhattacharya is shown telling staff that, based on his review of ...

The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week.

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from other high income countries that limit recommendations to older adults or ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...